Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

main

05_04 CBSACNY

CBSACNY "Generative AI: What It Means to Healthcare"

CBSACNY "Generative AI: What It Means to Healthcare"

Summary

Related Content

Teva’s Denosumab Biosimilar Candidate is Accepted for Review by FDA and EMA

Teva and mAbxience Add Additional Oncology Biosimilar Candidate, Expanding Strategic Partnership

Amgen Files BPCIA Complaint Against Fresenius Kabi Regarding Denosumab

Running for Rare for NORD

Florida District Court Concludes FCA’s Qui Tam Provision Is Unconstitutional

PTAB Institutes Eight More IPRs Filed by Merck on Johns Hopkins Pembrolizumab Patents

Fresenius and Formycon Receive EC and FDA Approval of Ustekinumab Biosimilar

Aflibercept Biosimilar Updates in Europe

Joshua Zachariah Named a Law360 MVP in Mergers & Acquisitions

Goodwin Once Again Number One for M&A

Goodwin UK Highly Ranked in Chambers UK 2025

Vicebio Announces $100 Million Series B Financing

Goodwin Advises Upstream Bio on $293 Million Upsized Initial Public Offering

Purespring Therapeutics Raises £80 Million

Goodwin Advises insitro on Strategic Agreements with Lilly to Advance Novel Treatments for Metabolic Diseases

Virios Therapeutics and Wex Pharmaceuticals Agree to Business Combination to Form Dogwood Therapeutics

Life Sciences